Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stake in Medtronic PLC $MDT

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Medtronic PLC (NYSE:MDT) by 4.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,631,648 shares of the medical technology company’s stock after purchasing an additional 112,717 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.21% of Medtronic worth $250,638,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Delos Wealth Advisors LLC purchased a new position in Medtronic during the 2nd quarter worth $27,000. Corundum Trust Company INC purchased a new position in shares of Medtronic during the third quarter worth about $27,000. Valley Wealth Managers Inc. acquired a new position in Medtronic in the 3rd quarter valued at about $29,000. Steigerwald Gordon & Koch Inc. purchased a new stake in Medtronic during the 3rd quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC acquired a new stake in Medtronic during the 3rd quarter worth approximately $34,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Down 0.0%

MDT stock opened at $96.71 on Thursday. The company has a market cap of $123.98 billion, a P/E ratio of 26.94, a P/E/G ratio of 2.43 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company’s 50-day moving average price is $98.98 and its 200 day moving average price is $96.83. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period last year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is presently 79.11%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Diabetes unit, MiniMed, has priced an IPO targeting up to $784M (28M shares at $25–$28). The move advances the planned spin‑off and could unlock value for Medtronic shareholders by creating a focused, public diabetes company. Medtronic’s MiniMed prices IPO at up to $784M
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor commercially across EMEA — the first app to combine InPen smart‑pen data with Simplera sensor data. Europe rollout expands MiniMed’s addressable market and supports recurring revenue from diabetes consumables and services. Medtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
• Positive Sentiment: Medtronic also reported FDA clearance for its Stealth AXiS spine surgical system (noted in coverage of its portfolio reshaping), which could boost its spine franchise and procedure‑related revenue over time. Medtronic Reshapes Portfolio With MiniMed IPO And Stealth AXiS Approval
• Neutral Sentiment: MiniMed’s IPO roadshow is underway with an investor presentation and expected pricing timeline; investors will watch subscription demand and final pricing for signals about appetite for diabetes assets. MiniMed announces launch of IPO roadshow
• Neutral Sentiment: Reports cite a potential MiniMed valuation near $7.9B—valuation and the amount Medtronic retains (or sells) will determine the magnitude of balance‑sheet and EPS impact. Medtronic’s diabetes unit MiniMed eyes $7.9 billion valuation in US IPO
• Neutral Sentiment: Analyst commentary (e.g., “inflection trade” coverage) suggests investors see a potential turnaround if new product approvals and the portfolio split accelerate growth; this is sentiment‑driven and depends on execution. Why the Medtronic (MDT) ‘Inflection Trade’ is Back On
• Negative Sentiment: Spin‑off/IPO risk — separating MiniMed reduces Medtronic’s near‑term revenue base and could introduce one‑time costs, dilution or changes to reported EPS and margin metrics; some investors may discount MDT shares until the post‑split capital allocation is clear. Medtronic’s diabetes business MiniMed looks for $784m in US IPO
• Negative Sentiment: Industry competition and lobbying developments (e.g., new diabetes sector leadership) highlight competitive pressure in diabetes tech that could affect market share and pricing over time. AdvaMed names Jake Leach as chair of diabetes sector

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. CICC Research began coverage on Medtronic in a report on Friday, January 30th. They set an “outperform” rating for the company. Wall Street Zen upgraded shares of Medtronic from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Citigroup began coverage on shares of Medtronic in a report on Tuesday, February 3rd. They issued a “buy” rating and a $117.00 target price on the stock. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Finally, Robert W. Baird lowered their price objective on Medtronic from $103.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, Medtronic has an average rating of “Moderate Buy” and an average price target of $110.84.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).